

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

Request for Proposal (RFP)

RFP Number: GHSC-PSM-TO2-2018-ARTEMISININ-BASED_FPP-IDIQ

For the routine procurement of: Artemisinin-Based and Artemisinin-Based Combination Finished Pharmaceutical Products (FPP)

And

Proposals for: Vendor Managed Inventory (VMI) Services for Artemisinin-Based and Artemisinin-Based Combination FPP

Issuance Date: August 15, 2018

Closing date: September 26, 2018 at 17:00 EST

For: USAID Global Health Supply Chain (GHSC) Program
Procurement and Supply Management (PSM) project

Funded By: United States Agency for International Development (USAID), Contract No./Task Order No. AID-OAA-I-15-00004/AID-OAA-TO-15-00009

Implemented By: Chemonics International Inc. (“Chemonics”, “GHSC-PSM”, or “the project”)

Attachments:

- Annex 1 – General Terms & Conditions
- Annex 2 – Required Certifications
- Annex 3 – Offer Cover Letter Template
- Annex 4 – Product Specifications and Technical Requirements
- Annex 5 – Price Quotation Form
- Annex 6 – Finished Pharmaceutical Product Questionnaire
- Annex 7 – Registration Status Form
- Annex 8 – Semi-Synthetic Artemisinin Access Questionnaire
- Annex 9 – GS1 Questionnaire
- Annex 10 – Artemisinin Supplier Detail
- Annex 11 – Packaging Specifications Template

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

Chemonics and its partners on GHSC-PSM (the GHSC-PSM Project) are committed to integrity in procurement, and only selects suppliers based on objective business criteria such as price and technical merit. Chemonics expects suppliers to comply with our Standards of Business Conduct, available at <https://www.chemonics.com/our-approach/standards-business-conduct/>.

The GHSC-PSM Project does not tolerate fraud, collusion among Offerors, falsified proposals/bids, bribery, or kickbacks. Any firm or individual violating these standards will be disqualified from this procurement, barred from future procurement opportunities, and may be reported to both USAID and the Office of the Inspector General.

Employees and agents of Chemonics and the GHSC-PSM Project are strictly prohibited from asking for or accepting any money, fee, commission, credit, gift, gratuity, object of value or compensation from current or potential vendors or suppliers in exchange for or as a reward for business. Employees and agents engaging in this conduct are subject to termination and will be reported to USAID and the Office of the Inspector General. In addition, Chemonics will inform USAID and the Office of the Inspector General of any supplier offers of money, fee, commission, credit, gift, gratuity, object of value, or compensation to obtain business.

Offerors responding to this RFP must include the following as part of the proposal submission:

- Disclose any close, familial, or financial relationships with Chemonics or the GHSC-PSM Project. For example, if an Offeror's cousin is employed by the GHSC-PSM Project, the Offeror must state this.

- Disclose any family or financial relationship with other Offerors submitting proposals. For example, if the Offeror's father owns a company that is submitting another proposal, the Offeror must state this.

- Certify that the prices in the offer have been arrived at independently, without any consultation, communication, or agreement with any other Offeror or competitor for the purpose of restricting competition.

- Certify that all information in the proposal and all supporting documentation are authentic and accurate.

- Certify understanding and agreement to the prohibitions against fraud, bribery and kickbacks.

Please contact Kristina Cartwright, Risk Manager, at PSMRiskManagement@ghsc-psm.org with any questions or concerns regarding the above information or to report any potential violations. Potential violations may also be reported directly to Chemonics' Washington office through the contact information listed on the website found at the hyperlink above.

******* ETHICAL AND BUSINESS CONDUCT REQUIREMENTS *******

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

I. Introduction to Global Health Supply Chain (GHSC) Project

The Global Health Supply Chain Program – Procurement and Supply Management (GHSC-PSM) Project (alternately referred to herein as “Chemonics” or “GHSC-PSM” or “Buyer”) is an official project of the United States Agency for International Development (USAID) implemented by Chemonics International and its consortium members. The purpose of GHSC-PSM is to ensure uninterrupted supplies of health commodities in support of USG-funded public health initiatives around the world. The project provides direct procurement and supply chain management support to the President’s Emergency Plan for AIDS Relief (PEPFAR), the President’s Malaria Initiative (PMI), and Population and Reproductive Health (PRH). GHSC-PSM supports health programs through the supply of a wide range of health commodities, including contraceptives and condoms, essential drugs; and select commodities for HIV/AIDS, malaria, maternal and child health, and infectious diseases.

II. Commodities and Services Requirements and Terms of Reference

1. Objectives and scope of the request for proposal

As part of project activities, the GHSC-PSM project requires the provision of several artemisinin-based and artemisinin-based combination finished pharmaceutical products (FPPs), including:

- Artemether/Lumefantrine (ALu) tablets
- Artesunate + Amodiaquine (ASAQ) FDC tablets
- Artesunate Suppositories
- Dihydroartemisinin/Piperaquine (DHA-PPQ) tablets
- Pyronaridine/Artesunate granules and tablets

Each are required in varying formulations and packaging for use in USAID-funded programs worldwide. RFP respondents are encouraged to offer as many of the requested product formulation types as possible.

Further, GHSC-PSM is soliciting potential VMI services for all product lines, as explained below. Offeror(s) do not have to provide quotes and proposals for VMI services; that component is encouraged, but optional. The resulting subcontracts will govern both routine procurement and VMI services as applicable. All proposals, which are deemed sufficiently responsive, will be evaluated.

Chemonics intends to enter into an indefinite delivery, indefinite quantity (IDIQ) subcontract with one or more Offeror(s) (alternatively referred to herein as “Subcontractor(s)” or “Supplier(s)” or “Vendor(s)”) who meet the criteria established in this RFP and are determined to be a responsible, eligible supplier for artemisinin-based FPPs.

Artemisinin-Based Finished Pharmaceutical Products (FPPs)

Following is a listing of the artemisinin-based and artemisinin-based combination FPPs for which proposals are requested.

GHSC-PSM anticipates ordering the following formulations and packaging of artemether/lumefantrine (ALu) over the course of base year contract(s) with up to three option years:

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

Description	Destination
artemether/lumefantrine 20 mg/120 mg tablets, dispersible, fixed-dose combination, 6x1 blister pack	All PMI-supported countries ¹
artemether/lumefantrine 20 mg/120 mg tablets, fixed-dose combination, 6x1 blister pack	All PMI-supported countries
artemether/lumefantrine 20 mg/120 mg tablets, dispersible, fixed-dose combination, 6x2 blister pack	All PMI-supported countries
artemether/lumefantrine 20 mg/120 mg tablets, fixed-dose combination, 6x2 blister pack	All PMI-supported countries
artemether/lumefantrine 20 mg/120 mg tablets, fixed-dose combination, 6x3 blister pack	All PMI-supported countries
artemether/lumefantrine 20 mg/120 mg tablets, fixed-dose combination, 6x4 blister pack	All PMI-supported countries
artemether/lumefantrine 40 mg/240 mg tablets, fixed-dose combination, 6x1 blister pack	All PMI-supported countries
artemether/lumefantrine 80 mg/480 mg tablets, fixed-dose combination, 6x1 blister pack	All PMI-supported countries

Additionally, GHSC-PSM anticipates ordering the following formulations and packaging of Artesunate + Amodiaquine (ASAQ) FDC tablets over the course of base year contract(s) with up to three option years:

Description	Destination
Artesunate + Amodiaquine FDC tablets, 25mg + 67.5mg, 3 tablets per blister	All PMI-supported countries
Artesunate + Amodiaquine FDC tablets, 50mg + 135mg, 3 tablets per blister	All PMI-supported countries
Artesunate + Amodiaquine FDC tablets, 100mg + 270mg, 3 tablets per blister	All PMI-supported countries
Artesunate + Amodiaquine FDC tablets, 100mg + 270mg, 6 tablets per blister	All PMI-supported countries

¹ There are 27 PMI focus countries in Africa and the Greater Mekong Sub region in Asia: <https://www.pmi.gov/where-we-work>. Additionally, non-PMI focus countries may procure any of these products during the period of performance of this IDIQ.

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

GHSC-PSM also anticipates ordering the following formulations and packaging of Artesunate Suppositories over the course of base year contract(s) with up to three option years:

Description	Destination
Artesunate 100 mg Suppository, 2 Suppositories	All PMI-supported countries
Artesunate 100 mg Suppository, 6 Suppositories	All PMI-supported countries
Artesunate 200 mg Suppository, 6 Suppositories	All PMI-supported countries
Artesunate 50 mg Suppository, 6 Suppositories	All PMI-supported countries

GHSC-PSM also anticipates ordering the following formulations and packaging of Dihydroartemisinin/Piperaquine over the course of base year contract(s) with up to three option years:

Description	Destination
Dihydroartemisinin/Piperaquine, 20 mg DHA/160 mg PQP Tablet, Blister, 3x1	All PMI-supported countries
Dihydroartemisinin/Piperaquine, 40 mg DHA/320 mg PQP Tablet, Blister, 3x1	All PMI-supported countries
Dihydroartemisinin/Piperaquine, 40 mg DHA/320 mg PQP Tablet, Blister, 6x1	All PMI-supported countries
Dihydroartemisinin/Piperaquine, 40 mg DHA/320 mg PQP Tablet, Blister, 9x1	All PMI-supported countries
Dihydroartemisinin/Piperaquine, 40 mg DHA/320 mg PQP Tablet, Blister, 12x1	All PMI-supported countries

Finally, GHSC-PSM also anticipates ordering the following formulations and packaging of Pyronaridine/Artesunate granules and tablets over the course of base year contract(s) with up to three option years:

Description	Destination
Pyronaridine/Artesunate 60 mg/20 mg Granules for Oral Suspension (Granules)	All PMI-supported countries
Pyronaridine/Artesunate 180 mg/60 mg Tablets	All PMI-supported countries

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

Moving forward, GHSC-PSM intends to solicit expressions of interest (EOIs) on the project website, to allow manufacturers the opportunity to present new or recently approved artemisinin-based FPPs, which are not yet eligible for this tender.

Artemisinin Supply Requirements

In an effort to stabilize access to active pharmaceutical ingredients, and as a result, commodity availability and pricing, all proposals (for routine orders and/or VMI) are required to provide evidence of agreement with one (or more) of a panel of approved artemisinin suppliers². A list of approved artemisinin suppliers will be provided to all parties who provide written intent to submit a proposal to this RFP (details provided in Section 2, below) by the required date. Proposal responses must include proof of a long-term agreement with one (or more) of the approved artemisinin suppliers. This must be provided in Annex 10, in the form of a redacted contract (or comparable detail).

During contract implementation, all IDIQ holders should anticipate regular reporting requirements to provide assurance of procurement agreements with the approved artemisinin suppliers, and continued usage of those agreements.

Additionally, Annex 8 – Semi-Synthetic Artemisinin (SSA) Access Questionnaire, expands on the artemisinin requirements, requesting details for supplier plans to ensure access to key dossier ingredients and is also required as a part of proposal submission.

Vendor Managed Inventory (VMI) Services

In addition to seeking offers for the provision of the above listed artemisinin-based FPPs, GHSC-PSM seeks creative proposals for vendor managed inventory (VMI)-type services for these products. The objective for any VMI-type agreement is to minimize lead time, allowing for emergency or short lead time orders to be placed and fulfilled quickly.

GHSC-PSM notionally anticipates the need for VMI-type services for the following commodities types and volumes:

Commodity Type	Volume
Artemether/Lumefantrine (ALu) tablets	<p>GHSC-PSM estimates an annual volume of 59 million treatments, of which one-quarter (or approximately 15 million treatments) would be fulfilled through a VMI-type approach.</p> <p>It is estimated VMI stock would turn over four times per year. Therefore, VMI estimates should be based on available stock being required at a level of up to 3.75 million treatments, through agreements with manufacturer(s).</p>
Artesunate + Amodiaquine (ASAQ) FDC tablets	GHSC-PSM estimates an annual volume of 17 million treatments, of which one-quarter (or 4.25 million treatments) would be fulfilled through a VMI-type approach.

² This solicitation is only for manufacturers of finished pharmaceutical products; therefore, Artemisinin suppliers should not submit proposals.

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

	It is estimated VMI stock would turn over four times per year. Therefore, VMI estimates should be based on available stock being required at a level of up to 1 million treatments, through agreements with manufacturer(s).
Artesunate Suppositories	GHSC-PSM estimates an annual volume of 1,000,000 treatments, of which one-quarter (or 250,000 treatments) would be fulfilled through a VMI-type approach. It is estimated VMI stock would turn over four times per year. Therefore, VMI estimates should be based on available stock being required at a level of up to 62,500 treatments, through agreements with manufacturer(s).
Dihydroartemisinin/Piperaquine Tablets	Volume estimates not available
Pyronaridine/Artesunate Granules and Tablets	Volume estimates not available

Any VMI-type proposal should state how you would significantly reduce lead times, to a level that is markedly lower than those we see today (roughly 7 – 12 weeks), through options like traditional VMI, a comparable approach such as The Global Fund Against AIDS Tuberculosis and Malaria (GFATM) Rapid Supply Mechanism, or other creative solutions for most competitive lead times. This could be accomplished through:

- a traditional approach in which the vendor procures ingredients, produces stock, packs it, and stores the stock based on agreed upon requirements, against which GHSC-PSM places orders, or;
- a creative approach in which the vendor adapts the traditional VMI approach to provide finished product within a competitive GAD timeframe. Likewise, GHSC-PSM would place orders, based on this approach. Proposed approaches should be vendor-specific and could potentially include the following examples:
 - a. vendor storage of product ingredients, available for rapid production, and packaging;
 - b. vendor storage of completed blisters, unpacked but available for rapid packaging;
 - c. any other creative solution the vendor might be able to provide which limits lead time and meets the GHSC-PSM requirements (below).

Required service parameters for either a traditional or creative approach to VMI, are listed below.

Under any VMI-type service arrangement, the manufacturer is requested to maintain, or have rapid access to, agreed-upon stock levels, against which GHSC-PSM will place orders based on countries' demand. The Offeror is responsible for replenishing and stocking the finished products and/or all required ingredients and packaging at agreed-upon levels and making them available to GHSC-PSM upon request. Products will be picked up by GHSC-PSM's freight forwarder under INCOTERM FCA. Please note, all ingredients and/or stock will be owned by the Offeror until GHSC-PSM places firm purchase orders under the resulting IDIQ sub-contract(s) and GHSC-PSM QA clears the goods.

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

Offeror interested in providing traditional VMI services must address the following service parameters in proposals. Responses to each of these parameters will be weighted equally in evaluation of proposals. VMI proposals will be ranked based on total score.

- a. **Stock volume-** How the offeror would maintain a specified volume, or the ability to produce this volume of artemisinin-based FPPs, and any storage limitations relevant to proposed VMI services.
- b. **Warehouse(s)-** Location(s) of proposed warehouse(s), already in existence or planned (if planned also indicate timing of warehouse availability). The offeror should clearly describe the status of compliance with national and international standards for storage of pharmaceutical products. This should include at a minimum a certificate or equivalent demonstrating the proposed facility complies with WHO Good Storage and Distribution Standards.
- c. **Insurance-** The Offeror shall be responsible for insurance of basic building and facility as well as insuring the product and/or product ingredients that will be housed in the facility.
- d. **Regulatory Requirements-** Clearly identify tax implications and/or time limitations for export cargo to be kept in the country of origin and propose how to address them. The agreement under which this procurement is financed does not permit the financing of any taxes, VAT, tariffs, duties, or other levies imposed by any laws in effect in the Cooperating Country. No such Cooperating Country taxes, VAT, charges, tariffs, duties or levies will be paid under an order resulting from this RFP. Offerors shall not assess any cooperating country taxes, duties, levies from which this USAID project is exempt.
- e. **Stock Visibility and Information-** All Goods with a shelf life, including all Pharmaceuticals, must be freshly manufactured, and thus have maximum possible shelf life. Goods with a maximum possible shelf life of less than 24 months shall have at least 85% of shelf life remaining when delivered. Goods with a maximum possible shelf life of more than 24 months shall have at least 24 months, or 85%, of shelf life remaining whichever is longer, when delivered. No Goods will be accepted which do not comply with these requirements unless Chemonics has agreed in writing to different requirements, in which case the Goods must strictly comply with those modified requirements. Related to these requirements, please address the following questions:
 - i. What is the lead time for product to be ready for sampling once a purchase order is provided?
 - ii. What is the timeframe for stock replenishment once stock is shipped?
- f. **Price-** Provide the **per pack price** for each formulation of the relevant artemisinin-based FPP fulfilled from inventory managed by the Offeror. The per pack price should include the same parameters as a FPP purchase in addition to any VMI-specific services such as inventory handling, tracking, and insurance. Please include all price quotations on the **Annex 5 Price Quotation Form. Please note that all prices offered should include and reflect the cost of samples required for quality assurance testing by a GHSC-PSM QA appointed testing laboratory.**
- g. Any other relevant terms and conditions related to the Offeror's proposed VMI services

Submitting a proposal for VMI services is encouraged, but optional. PSM is seeking proposals for VMI services for artemisinin-based FPPs from interested Offerors and may choose to utilize VMI services for a significant portion of these product orders annually, with the opportunity to adjust the volume up or down, dependent upon best value determinations.

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

2. Intent to Propose and Questions

Intent to propose and written questions or requests regarding the technical or administrative requirements of the RFP shall be submitted in writing to the following email addresses: skhederian@ghsc-psm.org and mrando@ghsc-psm.org. **Please include the RFP reference name GHSC-PSM-TO2-2018-ARTEMISININ-BASED_FPP-IDIQ in the subject line of all correspondence.**

The deadline for providing intent to propose and submission of questions is August 22, 2018 at 17:00 EST. Upon receipt of intent to propose submissions, Chemonics will provide the listing of approved artemisinin suppliers to all positive respondents. Proposal responses will only be considered from parties who have submitted an intent to propose.

Phone calls will not be accepted. Only the written answers issued by GHSC-PSM will be considered official and carry weight in the RFP process and subsequent evaluation. Any verbal information received from employees of the project, Chemonics International, Inc. or any other entity should not be considered as an official response to any questions regarding to this RFP.

RFP announcement	Aug. 15, 2018
Deadline for intent to submit and written questions/clarifications	Aug. 22, 2018
List of PMI approved suppliers provided/written answers provided	Aug. 27, 2018
Proposal due date	Sept. 26, 2018
Subcontract awards (estimated)	Jan. 1, 2019

Once the submission deadline has passed, GHSC-PSM may choose to engage in best and final offer (BAFO) negotiations with eligible participants.

3. Content of Proposals

Only one proposal for Artemisinin FPP and/or VMI services per vendor will be accepted.

Proposals should be submitted via email and must contain:

- a. Administrative proposal including all required documents listed in Annexes.
- b. Business proposal to be submitted strictly via Annex 5. **Please note that all prices offered should include and reflect the cost of bilingual packaging and of samples required for quality assurance testing by a GHSC-PSM QA appointed testing laboratory.**
- c. **For VMI services-** Offerors responding to this optional section shall provide a proposal for vendor-managed inventory (VMI) services for artemisinin-based FPPs that responds to the VMI service parameters noted above. The content of proposals should be no longer than 15 pages in length (supporting documentation can exceed 15 pages) and should be submitted in PDF format.

All documents submitted with the quotation must be signed, when applicable, by the bidding company's authorized representative and submitted in PDF format.

4. Instructions for submission

The Offerors are responsible for ensuring that their offers are received by GHSC-PSM in accordance with the instructions, terms, and conditions described in this RFP. Failure to adhere

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

to instructions described in this RFP may lead to disqualification of an offer from consideration. GHSC-PSM anticipates the award of IDIQ subcontract(s) with the Offeror(s) who meet(s) the criteria established in this RFP and is determined to be a responsible, eligible supplier for the specified item(s) and/or services. In order for an offer to be considered for this RFP, it must be complete, inclusive of Annex 8 Semi-Synthetic Artemisinin Access Questionnaire and Annex 10 Artemisinin Supplier Detail. Chemonics reserves the right to cancel the RFP or split orders across multiple successful Offerors in order to meet the needs of the GHSC-PSM project and the U.S. Government.

a. Offer deadline and submission protocol

Proposals should be prepared based on the guidelines listed in this RFP, along with a properly filled out and signed price quotation form.

Proposals and all correspondence and documents relating to the offer shall be in English. Proposals must be submitted no later than **September 26, 2018 at 17:00 EST. Please include the RFP reference name GHSC-PSM-TO2-2018-ARTEMISININ-BASED_FPP-IDIQ in the subject line of all correspondence.**

Offers received after the specified time and date will be considered late and will not be considered.

b. Source/Nationality/Manufacturer

All goods and services offered in response to this RFP or supplied under any resulting award must meet **USAID Geographic Code 935** in accordance with the United States Code of Federal Regulations (CFR), [22 CFR 228](#).

The Offeror may not offer or supply any commodities or services that are manufactured or assembled in, shipped from, transported through, or otherwise involving any of the following countries: Cuba, Iran, North Korea, Syria, or other countries or entities which may be subject to U.S. Government sanctions as per the OFCA list of sanctioned entities.

c. Technical specifications

Goods offered in the quotations must fully comply with the technical specifications listed in **Annex 1 General Terms and Conditions** and **Annex 4 Product and Service Specifications and Technical Requirements**. The proposals must contain detailed specifications of the products and services offered.

d. Proposals

Offerors are requested to provide quotations for all offered items using the **Annex 5 Price Quotation Form**. GHSC-PSM reserves the right to order more or less quantities, as required, during the period of performance of any award(s) resulting from this RFP.

e. Prices

For routine orders, please quote fixed unit prices on the following basis: FCA 2010 (Vendor Dock) Incoterm. Fixed unit prices are requested for each product type, as specified in Annex 5.

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

Any award(s) resulting from this RFP will be made in IDIQ sub-contracts, with fixed unit prices. During the life of any resulting award(s), Chemonics intends to periodically update order projections, and request updated fixed unit pricing from the subcontractor(s) (frequency could change at Chemonics' discretion). Units ordered during the ensuing period will be placed using these unit prices.

The fixed unit prices specified in the offer, and any subsequent subcontract, are all-inclusive total fixed unit prices covering performance of all subcontractor obligations under the subcontract. No additional sums will be payable for any change or escalation in the cost of materials, equipment, packaging or labor; the costs of cooperating with sampling, testing, inspection and other quality assurance requirements, when applicable; language (bilingual: French/English; Portuguese as needed), labeling and packaging requirements; warranty-related costs and charges; and, any and all other costs and charges of whatever description or amount in connection with, necessary for, or resulting from a subcontractor's required performance. Pricing must be presented in US dollars. Offers must remain valid for not less than ninety (90) calendar days after the offer deadline.

As part of the response to this RFP, in Annex 5, the Offerors are expected to provide an estimated lead time for each item quoted. Lead time means the period between the receipt of a firm order (Executed Subcontract or Purchase Order) and the time when the goods are ready for quality assurance inspection or otherwise transferred to Chemonics. The lead time estimate presented in an offer in response to this RFP must be upheld in the performance of any resulting contract.

All prices offered should include and reflect the cost of samples withdrawn by GHSC-PSM QA for testing purposes. The quantities withdrawn should be replaced (from a batch sampled by GHSC-PSM QA) at no additional cost.

For VMI, quotations in response to this RFP must be priced on a fixed-price, all-inclusive basis, including samples and all other costs. Pricing must be presented in US dollars. Offers must remain valid for not less than ninety (90) calendar days after the offer deadline. Chemonics reserves the right to revisit and renegotiate fixed prices periodically throughout the life of the contract.

The Offeror agrees that the price(s) quoted in response to this RFP represent the lowest price(s) at which the Offeror currently sells the Goods under comparable terms and conditions to any United States (U.S.) Government or U.S. Government-funded customers. If during the life of any subsequent subcontract, the subcontractor sells the Goods to any U.S. Government or U.S. Government-funded customer for a lower price, it will promptly inform Chemonics and execute an amendment to the subcontract so that such lower price applies to any pending or subsequent Goods delivered thereunder.

f. Period of performance

Chemonics anticipates the period of performance of any subcontract or agreement awarded under this RFP to be for approximately one year from the date of signature with the potential for up to three option years. The exact period of performance will be negotiated based on Offeror(s)' responses. Chemonics reserves the right to renegotiate pricing on a yearly basis.

g. Taxes and Value Added Tax (VAT)

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

The GHSC-PSM prime contract under which this procurement is funded does not permit the financing of any taxes, VAT, tariffs, duties, or other levies imposed by any laws in effect in the Cooperating Country. No such Cooperating Country taxes, VAT, charges, tariffs, duties or levies will be paid under an order resulting from this RFP. The Offeror shall not assess any cooperating country taxes, duties, levies, etc. from which this USAID project is exempt.

h. Eligibility

By submitting an offer in response to this RFP, the Offeror(s) certify that it and their principal officers are not debarred, suspended, or otherwise considered ineligible for an award by the U.S. Government. Chemonics will not award a contract or agreement to any firm that is debarred, suspended, or considered to be ineligible by the U.S. Government. Offerors shall be requested to provide a [DUNS number](#) in order to receive a sub-award valued at US \$30,000 or more.

5. Award criteria

GHSC-PSM anticipates the award of a subcontract with the Offeror(s) who best meet the criteria established in this RFP and are determined to be responsible, eligible suppliers for the specified items. Awards will be made based on a best value basis. WHO pre-qualification and/or SRA Approval are required. Price, registration status with recipient countries, quality assurance, API access status, lead time, past performance, and product portfolio (i.e. range of formulations), will be weighed equally in the determination of best value awards. For VMI service proposals, the service parameters specified in Section II – 1 of this solicitation will be weighted equally.

Please note, at this time we are requesting proposals only for products which are currently WHO pre-qualified or SRA-approved.

Once GHSC-PSM has executed contracts based on responses to this RFP, the intention is to issue an open-ended call for expressions of interest (EOIs) on the project website, to allow manufacturers the opportunity to present new or recently approved artemisinin-based FPPs, which are not yet eligible for this tender.

6. Overview of evaluation process

It is anticipated that award(s) will be made in accordance with a best value analysis on the basis of original quotations and the above referenced evaluation criteria among all suppliers who qualify. However, Chemonics reserves the right to conduct negotiations with and/or request clarifications from any Offeror prior to award.

Offerors that do not submit a proposal for VMI services for artemisinin-based FPPs will still be considered responsive if they submit a proposal for the routine supply of products as prescribed in Annex 5.

If there are significant deficiencies regarding responsiveness to the requirements of this RFP, an offer may be deemed “non-responsive” and thereby disqualified from consideration. Chemonics reserves the right to waive immaterial deficiencies at its discretion. In submitting a response to this RFP, the Offerors understand that USAID is not a party to this solicitation and the Offerors agree that any questions or concerns hereunder must be presented—in

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

writing with full explanations—in accordance with the guidance set forth in Section II.2, above, to Chemonics for consideration. Chemonics reserves the right to cancel this RFP at any time.

7. Terms and conditions

This is a Request for Proposal only. Issuance of this RFP does not in any way obligate Chemonics, the GHSC-PSM project, or USAID to make an award or pay for costs incurred by the Offeror in the preparation and submission of an offer.

Any award(s) resulting from this RFP will be in the form of an indefinite delivery, indefinite quantity subcontract with fixed unit prices.

This solicitation is subject to Chemonics' general terms and conditions and any attachments thereto. A copy of the general terms and conditions are attached to this RFP. Any resultant award will be governed by these terms and conditions. Chemonics reserves the right to make revisions to the content, order, and numbering of the provisions in the actual subcontract or agreement document prior to execution by Chemonics and the selected Offeror(s). Issuance of a subcontract and placement of any orders thereunder is subject to the availability of sufficient funds.

Risk of loss, damage, injury, or destruction of the goods shall be borne by the Offeror until custody is transferred upon delivery to GHSC-PSM on behalf of USAID.

United States law prohibits transactions with, and the provision of resources and support to, individuals and organizations associated with terrorism. The Subcontractor under any award resulting from this RFP must ensure compliance with these laws.

8. Product utilization

Items purchased by GHSC-PSM are not for use in the United States of America or for resale. As part of project activities, the GHSC-PSM requires the supply of selected artemether/lumefantrine, artesunate/amodiaquine, artesunate suppositories, DHA-PPQ and Pyronaridine/Artesunate for one or multiple countries supported by the US President's Malaria Initiative (PMI).

These products may not be used by recipient institutions for resale to commercial institutions or in response to bids on local or international tenders.

9. Orders under any resulting awards

Any award(s) resulting from this RFP will be in made in IDIQ sub-contracts, with fixed prices per unit. During the life of any resulting award(s), Chemonics intends to periodically update order projections, and request updated fixed unit pricing from the subcontractor(s) (frequency could change at Chemonics' discretion). Units ordered during the ensuing period will be placed using these unit prices.

Chemonics will not release a request for quotation (RFQ) for each order. However, Chemonics reserves the right to issue an RFQ to the Offeror(s) awarded any subcontract if deemed necessary, and Chemonics reserves the right to revisit and renegotiate prices

USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

periodically throughout the life of the contract. At the time of order, Chemonics will validate registration status and lead time via email, and determine the best value offeror for each order under any resulting awards based on the proposals from successful Offeror(s) submitted in response to this RFP, using the following criteria:

- a. Ability to meet order specifications, such as formulation and quantity
- b. Registration status and/or ability to import product(s) into the requesting country
- c. Past performance on previous orders, including quality, timeliness, and cost control
- d. Potential impact on other orders placed with the contractor
- e. Compliance with negotiated artemisinin supply plan (use of SSA and/or nature of long-term agreement with approved artemisinin supplier)
- f. Potential impact on GHSC-PSM supply chain
- g. Potential implications for total landed cost
- h. Lead time
- i. Unit price